$OLMA Cashflow Statement | Understand Stock

$OLMA

$6.62 +$0.21 (3.28%) Close

$OLMA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Non-cash lease expense
Premium amortization and discount accretion on marketable securities, net
Non-cash interest income on marketable securities
Stock-based compensation expense, including employee stock purchase plan expense
Loss on disposal of equipment
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other assets
Other assets and long-term deposits
Accounts payable
Other current liabilities
Operating lease liabilities

Net cash used in operating activities

Cash flows from investing activities:
Purchase of equipment
Disposal of fixed assets
Maturities of marketable securities
Purchases of marketable securities
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issuance of shares upon follow-on public offering, net of issuance costs of $13,110
Proceeds from issuance of shares under at-the-market offering, net of issuance costs of $166
Proceeds from 2024 private placement, net of issuance costs of $6,498
Payment of issuance costs for shares issued under 2024 private placement
Proceeds from borrowings under Credit Facility (Note 13)
Proceeds from exercise of stock options
Proceeds from issuance of common stock under employee stock purchase plan
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Reclassification of prepaid expenses and other current liabilities into other assets
Vesting of early exercised stock options
Issuance costs for equity private placement not paid in cash by the end of period
Supplemental disclosure of cash flow information
Exchange common stock shares for pre-funded warrants
Research and development project deposit applied against final study invoices
Right-of-use asset obtained in exchange for operating lease liabilities
Unpaid issuance costs related to follow-on offering and 2024 private placement
Research and development project deposit applied against study invoices
System implementation cost included in other current liabilities

Comments